Table 3.
Functional capacity and hemodynamics with riociguat and 6 months after BPA.
| n | Under riociguat | n | 6 months after BPA | P value | |
|---|---|---|---|---|---|
| Exercise capacity | |||||
| WHO FC (n (%)) | 36 | 36 | 0.0001 | ||
| I | 0 (0) | 18 (50.0) | |||
| II | 7 (19.4) | 16 (44.4) | |||
| III | 18 (50.0) | 2 (5.6) | |||
| IV | 11 (30.6) | 0 (0) | |||
| 6MWD (m) | 32 | 409 ± 102 | 30 | 467 ± 95 | 0.0001 |
| Hemodynamics | |||||
| Right atrial pressure (mmHg) | 36 | 7 ± 4 | 36 | 6 ± 3 | 0.02 |
| mPAP (mmHg) | 36 | 43 ± 12 | 36 | 34 ± 14 | 0.0001 |
| sPAP (mmHg) | 36 | 74 ± 21 | 36 | 59 ± 25 | 0.0001 |
| dPAP (mmHg) | 36 | 25 ± 7 | 36 | 18 ± 8 | 0.0001 |
| PAWP (mmHg) | 36 | 10 ± 3 | 36 | 10 ± 3 | 0.92 |
| DPG (mmHg) | 36 | 15 ± 7 | 36 | 8 ± 8 | 0.0001 |
| TPG (mmHg) | 36 | 33 ± 11 | 36 | 24 ± 13 | 0.0001 |
| CO (L/min) | 36 | 5.0 ± 1.5 | 36 | 5.5 ± 1.3 | 0.0001 |
| CI (L/min/m2) | 36 | 2.6 ± 0.7 | 36 | 2.9 ± 0.6 | 0.02 |
| PVR (dyn·s·cm–5) | 36 | 517 ± 279 | 36 | 360 ± 175 | 0.0001 |
| PAC (mL/mmHg) | 36 | 1.4 ± 0.6 | 36 | 2.3 ± 1.0 | 0.0001 |
| HR (bpm) | 36 | 78 ± 12 | 36 | 70 ± 11 | 0.001 |
| Laboratory findings | |||||
| NT-proBNP (ng/L) (median (IQR)) | 29 | 1,010 (128–1,887) | 35 | 150 (75–385) | 0.0001 |
| Creatinine* (mg/dL) | 28 | 0.98 ± 0.31 | 36 | 0.91 ± 0.28 | 0.02 |
| eGFR (mL/min) | 28 | 82 ± 28 | 36 | 94 ± 59 | 0.05 |
Values are given as mean ± SD unless otherwise indicated.
*
To convert mg/dL to mmol/L divide by 11.3.
WHO, World Health Organization; mPAP, mean pulmonary artery pressure; sPAP, systolic pulmonary artery pressure; dPAP, diastolic pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; DPG, diastolic pressure gradient; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index; PVR, pulmonary vascular resistance; PAC, pulmonary arterial compliance; HR, heart rate; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; eGFR, estimated glomerular filtration rate.